It is important to note that weight loss outcomes may vary between individuals and depend on various factors such as adherence to treatment, lifestyle modifications, and overall health
The transparent reporting supports scientific rigor and regulatory compliance
Phase 3 data from the TRIUMPH-4 study, released in December of last year, showed 28.7% average body weight loss at the 12 mg dose over 68 weeks
Semaglutide reduces heavy drinking and overall alcohol intake The study included 108 participants (54 per group), of whom only 88 completed the trial
Yes, semaglutide therapy can be used by individuals without diabetes who are struggling with obesity and have a body mass index (BMI) of 30 or higher
Peptide Therapy We offer a variety of peptides to accelerate weight loss, improve muscle growth and suppress appetite, increase energy, and more